NI202100009A - Métodos para reducir la necesidad de revascu - Google Patents
Métodos para reducir la necesidad de revascuInfo
- Publication number
- NI202100009A NI202100009A NI202100009A NI202100009A NI202100009A NI 202100009 A NI202100009 A NI 202100009A NI 202100009 A NI202100009 A NI 202100009A NI 202100009 A NI202100009 A NI 202100009A NI 202100009 A NI202100009 A NI 202100009A
- Authority
- NI
- Nicaragua
- Prior art keywords
- need
- revascu
- methods
- reduce
- subject
- Prior art date
Links
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 230000000250 revascularization Effects 0.000 abstract 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 1
- 125000004494 ethyl ester group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719404P | 2018-08-17 | 2018-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202100009A true NI202100009A (es) | 2021-06-22 |
Family
ID=69524891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202100009A NI202100009A (es) | 2018-08-17 | 2021-02-16 | Métodos para reducir la necesidad de revascu |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220362200A1 (https=) |
| EP (1) | EP3836914A4 (https=) |
| JP (1) | JP2021534185A (https=) |
| KR (1) | KR20210047312A (https=) |
| CN (1) | CN112912071A (https=) |
| AU (2) | AU2019321568B2 (https=) |
| BR (1) | BR112021002884A2 (https=) |
| CL (3) | CL2021000400A1 (https=) |
| EA (1) | EA202190547A1 (https=) |
| IL (1) | IL280643A (https=) |
| MA (1) | MA52680A1 (https=) |
| MX (1) | MX2021001906A (https=) |
| NI (1) | NI202100009A (https=) |
| PH (1) | PH12021550328A1 (https=) |
| SG (1) | SG11202101562UA (https=) |
| TN (1) | TN2021000028A1 (https=) |
| WO (1) | WO2020037153A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SG10201605794PA (en) | 2009-04-29 | 2016-09-29 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| AU2010298222B2 (en) | 2009-09-23 | 2017-01-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| NZ727849A (en) | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US12430998B2 (en) | 2018-09-14 | 2025-09-30 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| US11645899B2 (en) | 2018-09-14 | 2023-05-09 | Avive Solutions, Inc. | Responder network |
| US11640755B2 (en) | 2018-09-14 | 2023-05-02 | Avive Solutions, Inc. | Real time defibrillator incident data |
| LT3750536T (lt) | 2018-09-24 | 2026-03-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| WO2021102246A1 (en) * | 2019-11-21 | 2021-05-27 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CA3217098A1 (en) * | 2021-04-29 | 2022-11-03 | Richard Louis Dunbar | Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090239927A1 (en) * | 2004-12-06 | 2009-09-24 | George Bobotas | Statin and Omega-3 Fatty Acids For Lipid Therapy |
| JP2009544701A (ja) * | 2006-07-21 | 2009-12-17 | リライアント・ファーマシューティカルズ・インコーポレイテッド | オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 |
| NZ727849A (en) * | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20140322314A1 (en) * | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| AU2015231713B2 (en) * | 2014-03-17 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Methods for reducing cardiovascular risk |
| US10406130B2 (en) * | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| DK3275438T3 (da) * | 2016-07-29 | 2021-01-18 | Kowa Co | Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko |
-
2019
- 2019-08-15 CN CN201980069084.5A patent/CN112912071A/zh active Pending
- 2019-08-15 MA MA52680A patent/MA52680A1/fr unknown
- 2019-08-15 EP EP19849946.9A patent/EP3836914A4/en active Pending
- 2019-08-15 SG SG11202101562UA patent/SG11202101562UA/en unknown
- 2019-08-15 WO PCT/US2019/046710 patent/WO2020037153A1/en not_active Ceased
- 2019-08-15 MX MX2021001906A patent/MX2021001906A/es unknown
- 2019-08-15 KR KR1020217007524A patent/KR20210047312A/ko not_active Ceased
- 2019-08-15 BR BR112021002884-6A patent/BR112021002884A2/pt not_active Application Discontinuation
- 2019-08-15 TN TNP/2021/000028A patent/TN2021000028A1/en unknown
- 2019-08-15 US US17/275,576 patent/US20220362200A1/en not_active Abandoned
- 2019-08-15 JP JP2021507918A patent/JP2021534185A/ja active Pending
- 2019-08-15 AU AU2019321568A patent/AU2019321568B2/en active Active
- 2019-08-15 EA EA202190547A patent/EA202190547A1/ru unknown
-
2021
- 2021-02-04 IL IL280643A patent/IL280643A/en unknown
- 2021-02-16 PH PH12021550328A patent/PH12021550328A1/en unknown
- 2021-02-16 NI NI202100009A patent/NI202100009A/es unknown
- 2021-02-16 CL CL2021000400A patent/CL2021000400A1/es unknown
- 2021-12-03 CL CL2021003222A patent/CL2021003222A1/es unknown
- 2021-12-03 CL CL2021003221A patent/CL2021003221A1/es unknown
-
2024
- 2024-08-21 US US18/810,687 patent/US20250186386A1/en active Pending
-
2025
- 2025-04-22 AU AU2025202801A patent/AU2025202801A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3836914A1 (en) | 2021-06-23 |
| EP3836914A4 (en) | 2022-05-18 |
| US20250186386A1 (en) | 2025-06-12 |
| KR20210047312A (ko) | 2021-04-29 |
| BR112021002884A2 (pt) | 2021-05-11 |
| IL280643A (en) | 2021-03-25 |
| US20220362200A1 (en) | 2022-11-17 |
| EA202190547A1 (ru) | 2021-04-27 |
| WO2020037153A1 (en) | 2020-02-20 |
| MX2021001906A (es) | 2021-04-28 |
| SG11202101562UA (en) | 2021-03-30 |
| TN2021000028A1 (en) | 2022-10-03 |
| CL2021003221A1 (es) | 2022-07-22 |
| MA52680A1 (fr) | 2021-11-30 |
| AU2025202801A9 (en) | 2026-03-05 |
| CA3109774A1 (en) | 2020-02-20 |
| AU2019321568B2 (en) | 2025-01-30 |
| PH12021550328A1 (en) | 2021-10-04 |
| CL2021003222A1 (es) | 2022-07-22 |
| CL2021000400A1 (es) | 2021-07-02 |
| AU2019321568A1 (en) | 2021-03-11 |
| AU2025202801A1 (en) | 2025-05-08 |
| CN112912071A (zh) | 2021-06-04 |
| JP2021534185A (ja) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202100009A (es) | Métodos para reducir la necesidad de revascu | |
| CL2023000767A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| MX2022005467A (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto con fibrilación auricular y/o aleteo auricular. | |
| MX2020008890A (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| BR112021011368A2 (pt) | Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| MX384262B (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| MX2022014577A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| ECSP15050273A (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
| MX2023011720A (es) | Una composicion para su uso en el tratamiento de mhc-i-opatias. | |
| CO2023000194A2 (es) | Administración de sulcardina para el tratamiento de fibrilación auricular aguda | |
| CL2023001739A1 (es) | Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina | |
| MX2023006728A (es) | Esteres de acido dicarboxilico para inducir un efecto analgesico. | |
| PH12021500016A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| ZA202310640B (en) | Methods of reducing the risk of heart failure | |
| ES2524645B1 (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
| EA202190859A8 (ru) | Способы снижения риска сердечно-сосудистых событий у субъекта | |
| CO2026002830A2 (es) | Inhibidor del inflamasoma nlrp3 y su uso | |
| AR100621A1 (es) | COMPUESTO INHIBIDOR DE FOSFOINOSÍTIDO-3-QUINASA d, COMPOSICIÓN FARMACÉUTICA, USO, MÉTODO | |
| BR112015029693A2 (pt) | formulações farmacêuticas de um inibidor de hif hidroxilase | |
| BR112014033118A8 (pt) | Combinações farmacêuticas de um inibidor de cdk4/6 e um inibidor de b-raf |